HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sibu picked up by GNC

This article was originally published in The Rose Sheet

Executive Summary

Marketer of premium beauty and wellness products based on the sea buckthorn berry has secured space for its products in 1,300 corporate 1GNC stores. All GNC stores will carry Sibu Revitalize & Renew liquid supplement, and 600 of those also will carry Cellular Support gel caps, Repair & Protect daily face cream and Cleanse & Detox facial soap. Sibu products also are available at SibuBeauty.com and health and natural food stores nationwide, including Whole Foods (2"The Rose Sheet" Oct. 19, 2009). Sibu Beauty touts its products - built around the "Holy Fruit of the Himalayas" - as 100% natural, preservative-, paraben- and cruelty-free, and devoid of dairy, wheat, gluten, sodium, yeast or preservatives

You may also be interested in...



Sibu Beauty Anoints Skin With "Holy Fruit Of The Himalayas"

Sea buckthorn berries grown and harvested exclusively for Sibu Beauty in the Tibetan Himalayans are "more potent and hardy berries than typical sea buckthorn," the Midvale, Utah firm says

As Casgevy, Lyfgenia Launches Proceed, CRISPR And bluebird bio CEOs Reassure

The CEOs of bluebird bio and CRISPR Therapeutics hope to inspire investor confidence that their gene-based therapies for sickle cell disease and beta thalassemia will be widely reimbursed in the US and EU.

Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings

Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS016980

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel